Metly, a Barcelona, Spain-based intelligence layer for pharmaceutical business development teams, has raised a €520,000 pre-seed round.
Investors
The oversubscribed round was led by Encomenda, with participation from Ona Capital, Dozen Investments, and strategic angel investors, including Roberto Urbez, former Bristol Myers Squibb executive.
Encomenda is a Spanish early-stage venture capital firm focused on investing in tech-driven startups (AI, SaaS, fintech, blockchain, etc.) at the pre-seed and seed stages. Headquartered in Barcelona, Spain, the firm also provides hands-on mentoring, strategic advice, and operational support.
Metly Use of Funds
The company will use the funds to scale its AI technology, expand its technical and commercial teams, and drive international growth, particularly in the US and China.
About Metly
Metly provides an AI-powered intelligence platform built specifically for pharmaceutical business development teams. It helps companies identify and assess licensing and manufacturing opportunities, connect with partners, and streamline traditionally manual processes that rely heavily on personal networks and spreadsheets. The platform already hosts more than 35,000 licensed products from 550 global licensors, with expansion into the US and China underway.
Funding Details
Company: Metly
Raised: €0.52M
Round: Pre-Seed
Funding Date: July 2025
Lead Investor: Encomenda
Additional Investors: Ona Capital, Dozen Investments, Roberto Urbez (angel)
Company Website: https://www.meetmetly.com/
Software Category: Pharmaceutical Business Development / AI Intelligence Platform
Source: https://tech.eu/2025/07/22/metly-raises-eur520k-in-a-pre-seed-round-to-accelerate-pharma-product-launches-with-ai/